DSGN

Design Therapeutics, Inc.

No convergence signal this quarter — shown because tracked funds have filed 13D/G on this stock.

Days to cover (short int.)

7.3d↓-1.5%

as of 2026-09-15

News Summary

Positive

Design Therapeutics delivered a modest earnings beat in Q2 2026 (-$0.32 vs. -$0.35 estimate) while maintaining a strong cash position of $207.4M, providing runway for clinical programs. The company is executing on its pipeline with RESTORE-FA trial modifications expected to yield 12-week data in Q1 2027, DT-818 dosing initiated in myotonic dystrophy, and preclinical work advancing on Huntington's disease, garnering Wells Fargo's October 2026 initiation with an overweight rating and $26 price target (112% upside).

Fund 13D/13G Filings (4)

Tracked funds' beneficial-ownership filings on this stock — disclosed within days of a position change, fresher than the quarterly 13F. Since Filing compares the stock to SPY from the filing date (shown for filings within the last 90 days).

Fund	Form	∆ Shares	% of Class	Since Filing	Filed	Src
Point72	SC 13G/A	−831K	3.8%	-16.3% vs SPY -16.3% abs	2026-08-14	↗
Point72	SC 13G	+475K	5.1%	+38.7% vs SPY +43.5% abs	2026-06-09	↗
Point72	SC 13G/A	—	4.4%	-5.4% vs SPY +0.1% abs	2026-05-15	↗
Point72	SC 13G/A	—	9.4%	—	2026-02-17	↗

Tracked Funds Holding (1)

Fund	Manager	Shares Held	Position Value
Point72	Steve Cohen	2.4M	$34M

Quarter-end 13F positions for the tracked funds holding this stock.